These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30148691)

  • 1. Comparative effectiveness of H7N9 vaccines in healthy individuals.
    Zheng D; Gao F; Zhao C; Ding Y; Cao Y; Yang T; Xu X; Chen Z
    Hum Vaccin Immunother; 2019; 15(1):80-90. PubMed ID: 30148691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
    Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.
    Feldman RA; Fuhr R; Smolenov I; Mick Ribeiro A; Panther L; Watson M; Senn JJ; Smith M; Almarsson Ӧ; Pujar HS; Laska ME; Thompson J; Zaks T; Ciaramella G
    Vaccine; 2019 May; 37(25):3326-3334. PubMed ID: 31079849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial.
    Wu UI; Hsieh SM; Lee WS; Wang NC; Kung HC; Ou TY; Chen FL; Lin TY; Chen YC; Chang SC
    Vaccine; 2017 Jul; 35(33):4099-4104. PubMed ID: 28668573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).
    Oshansky CM; Zhou J; Gao Y; Schweinle JE; Biscardi K; DeBeauchamp J; Pavetto C; Wollish A; ; Webby RJ; Cioce V; Donis RO; Bright RA
    Vaccine; 2019 Jan; 37(3):435-443. PubMed ID: 30553570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic and mucosal humoral immune responses induced by the JY-adjuvanted nasal spray H7N9 vaccine in mice.
    Xu J; Li S; Wang X; Liu J; Shan P; Zhou Y; Zhao J; Wang Z; Xu C; Chen M; Chen Z; Zhao K; Qu D
    Emerg Microbes Infect; 2018 Aug; 7(1):140. PubMed ID: 30076293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.
    Chada KE; Forshee R; Golding H; Anderson S; Yang H
    Vaccine; 2017 May; 35(24):3162-3170. PubMed ID: 28483200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and Safety of Pandemic Influenza H5N1 Vaccines in Healthy Adults through Meta-Analysis.
    Guo Q; Liu Z; Gao J; Zhou J; Hu W; Cun Y; Li W; Liao G
    Cell Physiol Biochem; 2016; 40(5):921-932. PubMed ID: 27941323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.
    Lin J; Zhang J; Dong X; Fang H; Chen J; Su N; Gao Q; Zhang Z; Liu Y; Wang Z; Yang M; Sun R; Li C; Lin S; Ji M; Liu Y; Wang X; Wood J; Feng Z; Wang Y; Yin W
    Lancet; 2006 Sep; 368(9540):991-7. PubMed ID: 16980114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
    J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial.
    Vanni T; Thomé BC; Sparrow E; Friede M; Fox CB; Beckmann AM; Huynh C; Mondini G; Silveira DH; Viscondi JYK; Braga PE; Silva AD; Salomão MDG; Piorelli RO; Santos JP; Gattás VL; Lucchesi MBB; Oliveira MMM; Koike ME; Kallas EG; Campos LMA; Coelho EB; Siqueira MAM; Garcia CC; Miranda MD; Paiva TM; Timenetsky MDCST; Adami EA; Akamatsu MA; Ho PL; Precioso AR
    PLoS One; 2022; 17(10):e0274943. PubMed ID: 36256646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the immunogenicity and bioactivities of a split influenza A/H7N9 vaccine mixed with MF59 adjuvant in BALB/c mice.
    Ou H; Yao H; Yao W; Wu N; Wu X; Han C; Cheng L; Chen K; Chen H; Li L
    Vaccine; 2016 Apr; 34(20):2362-70. PubMed ID: 27013436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
    Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
    Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of the safety and pathogenicity of a live attenuated recombinant influenza A/H7N9 seed strain and corresponding MF59-adjuvanted split vaccine.
    Ou H; Yao W; Wu N; Wang FX; Weng T; Han C; Lu X; Yu D; Wu H; Cheng L; Chen H; Yao H; Li L
    Oncotarget; 2016 Dec; 7(49):81012-81025. PubMed ID: 27768591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
    Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
    Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.
    Bart SA; Hohenboken M; Della Cioppa G; Narasimhan V; Dormitzer PR; Kanesa-Thasan N
    Sci Transl Med; 2014 Apr; 6(234):234ra55. PubMed ID: 24786323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.